Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 21 to 30 of 2440 total matches.
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
to 2% of NSCLC cases
have genetic rearrangements of the ROS protooncogene
1 (ROS1) gene. The standard ...
The FDA has approved the oral tyrosine kinase
inhibitor repotrectinib (Augtyro – BMS) for treatment
of locally advanced or metastatic ROS1-positive
non-small cell lung cancer (NSCLC) in adults.
Repotrectinib is the third oral tyrosine kinase inhibitor
to be approved for this indication in the US; crizotinib
(Xalkori) and entrectinib (Rozlytrek) were approved
earlier.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e36-7 doi:10.58347/tml.2024.1696g | Show Introduction Hide Introduction
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
survival was also statistically significantly longer
with fruquintinib in both trials.1,2
MECHANISM ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5 doi:10.58347/tml.2024.1696f | Show Introduction Hide Introduction
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
expression. The drug mimics the effect
of hypoxia on stimulation of erythropoiesis.1
Table 1. Pharmacology ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed ...
The FDA has approved cantharidin 0.7% solution
(Ycanth – Verrica) for topical treatment of molluscum
contagiosum in patients ≥2 years old. Ycanth
was the first drug to be approved in the US for this
indication. A 10.3% gel formulation of berdazimer
(Zelsuvmi), a nitric oxide-releasing agent, has
also been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed in a future issue.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):27-9 doi:10.58347/tml.2024.1696b | Show Introduction Hide Introduction
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
blocker efgartigimod alfa
(Vyvgart; Vyvgart Hytrulo)1 and the complement
inhibitors eculizumab (Soliris ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal
Fc receptor (FcRn) blocker, has been approved by the
FDA for treatment of generalized myasthenia gravis in
adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
It is the first drug to be approved for treatment of
generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the
FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart
Hytrulo) and the complement inhibitors eculizumab
(Soliris), ravulizumab (Ultomiris), and zilucoplan
(Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31 doi:10.58347/tml.2024.1696c | Show Introduction Hide Introduction
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
Balfaxar and Kcentra contain the same three
factors and significant amounts of factor VII.1 Four-factor ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
in 2016.1
PATHOGENESIS
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization ...
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20 doi:10.58347/tml.2024.1695a | Show Introduction Hide Introduction
Drugs for Rosacea
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
scarring occur rarely.1,2
TOPICAL THERAPY
Topical therapies are used for initial treatment of mild ...
Rosacea is a common, chronic inflammatory facial
eruption of unknown cause. It is more prevalent
in women than in men, and disease onset typically
occurs after age 30. Rosacea is characterized
by erythema, telangiectasia, and flushing, and
sometimes by recurrent, progressive crops of
acneiform papules and pustules, usually on the
central part of the face. Some patients develop
granulomas and tissue hypertrophy, which may lead
to rhinophyma (a bulbous nose), particularly in men.
Blepharitis and conjunctivitis are common. Keratitis
and corneal scarring occur rarely.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):21-2 doi:10.58347/tml.2024.1695b | Show Introduction Hide Introduction
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
with reduced quality of life and increased
hospitalization and mortality.1 Injectafer is the first
IV iron ...
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve exercise
capacity. Iron deficiency is present in approximately
30% of patients with heart failure; it has been
associated with reduced quality of life and increased
hospitalization and mortality. Injectafer is the first
IV iron preparation to be approved for this indication.
It was previously approved for treatment of iron
deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4 doi:10.58347/tml.2024.1695d | Show Introduction Hide Introduction
Comparison Table: Some Topical Drugs for Rosacea (online only)
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
in women
Apply once/day 481.60/30 g
637.50/30 g
Ivermectin – generic
Soolantra (Galderma)
1% cream Yes ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22 doi:10.58347/tml.2024.1695c | Show Introduction Hide Introduction